Volume | 61,877,221 |
|
|||||
News | - | ||||||
Day High | 0.0875 | Low High |
|||||
Day Low | 0.0713 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jaguar Health Inc | JAGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.0725 | 0.0713 | 0.0875 | 0.0899 | 0.0729 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
26,279 | 61,877,221 | $ 0.077954 | $ 4,823,577 | - | 0.0512 - 1.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:48 | 1 | $ 0.0856 | USD |
Jaguar Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.57M | 50.76M | - | 11.96M | -47.45M | -0.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jaguar Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JAGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.0841 | 0.0898 | 0.0653 | 0.0741243 | 50,501,047 | 0.0029 | 3.45% |
1 Month | 0.0591 | 0.1628 | 0.058 | 0.0989343 | 78,611,974 | 0.0279 | 47.21% |
3 Months | 0.1406 | 0.1628 | 0.0512 | 0.0963938 | 39,162,792 | -0.0536 | -38.12% |
6 Months | 0.265 | 0.529 | 0.0512 | 0.1296425 | 21,499,019 | -0.178 | -67.17% |
1 Year | 1.00 | 1.22 | 0.0512 | 0.1760122 | 11,565,666 | -0.913 | -91.30% |
3 Years | 135.75 | 228.00 | 0.0512 | 31.60 | 7,074,726 | -135.66 | -99.94% |
5 Years | 1,640.625 | 1,916.25 | 0.0512 | 109.28 | 8,485,685 | -1,640.54 | -99.99% |
Jaguar Health Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. |